



## LETTER TO THE EDITOR

## Intermittent versus equivalent constant-load cycle training in COVID-19 patients



Dear Editor,

While the need to implement evidence-based training following COVID-19 is imperative, no consensus exists as to how such programmes should be designed.<sup>1-3</sup> Between 20 July 2020 and 30 April 2021, we assessed tolerability and safety of high-intensity constant-load exercise (CLE) and high-intensity intermittent exercise (IE) in 14 patients presenting pneumonia and acute respiratory failure (ARF) (mean age: 63±13 years) with ongoing symptomatic COVID-19 from 4 to 12 weeks following the infection. Anthropometric data, body mass index (BMI), and the number of comorbidities were recorded. Patients undertook spirometry (FEV<sub>1</sub>, FVC, FEV<sub>1</sub>/FVC, transfer factor for Carbon Monoxide (DLCO), blood gases in room air (PaO<sub>2</sub>, PaCO<sub>2</sub>, pH), functional status (the Short Physical Performance Battery-SPPB test and the 6-minute walking distance [6MWD: in meters and as a percentage of predicted]), an incremental cardiopulmonary exercise test (CPET) [assessing oxygen uptake (VO<sub>2</sub>), carbon dioxide output (VCO<sub>2</sub>), oxygen uptake at the anaerobic threshold (AT), respiratory exchange ratio (RER), minute ventilation (V<sub>E</sub>), tidal volume (V<sub>T</sub>) and respiratory rate] using a portable metabolimeter; transcutaneous carbon dioxide tension (TcCO<sub>2</sub>) was also recorded continuously. In this crossover study (Ethics Committee approval on 30 June 2020, Protocol No. 2449CE), training exercise intensity was balanced to provide the same average work rate for IE and CLE modalities. CLE was set at 70% of peak work rate (WR<sub>peak</sub>) and IE consisted of one minute of exercise at 100% WR<sub>peak</sub>, alternated with one minute at 40% WR<sub>peak</sub>, to the limit of tolerance (T<sub>lim</sub>). Dyspnea and leg muscle discomfort (1-10 Borg scale), heart rate and safety were assessed. Of the 220 consecutively admitted patients at the Respiratory Rehabilitative Unit - ICS Maugeri of Lumezzane (BS) - as inpatient and outpatient between 20 July 2020 and 30 April 2021, 14 patients were eligible for the study. We excluded from this study 63 patients presenting symptoms for less than four weeks following infection, 35 patients with more than 12 weeks following infection, 44 clinically unstable patients, 20 patients with severe orthopedic diseases, 15 patients with cognitive impairment, 29 patients with previous severe

heart disease (congestive heart disease, severe aortic stenosis, atrial fibrillation). We did not successfully exclude patients for technical reasons or missing data.

Table 1 shows the study population and cardiorespiratory function at peak exercise; two patients presented mitral valve insufficiency and one chronic atrial fibrillation, while two patients suffered from mild COPD. At study entry, patients showed breathlessness (71.4%), fatigue (64.3%), cough (14.4%), palpitations (21.4%) and pain (35.7%), respectively. Patients presented the following lung function data: FEV<sub>1</sub> % predicted (prd): 83.2±15.7, FVC, % prd: 79.1±15.8., FEV<sub>1</sub>/FVC: 84.1±8.5, DLCO % prd: 56.7±26.6, PaO<sub>2</sub>: 73.7±11.8 mmHg, PaCO<sub>2</sub>: 36.9±3.01 mmHg. We reported no adverse events for either of the two modalities. We detected no ECG abnormalities during or after IE or CLE. At peak exercise, WR<sub>peak</sub> and V̇O<sub>2peak</sub> were reduced below normal predicted levels. Premature metabolic acidosis was evident by the low fraction of predicted normal V̇O<sub>2</sub> when the anaerobic threshold (AT) was detected (AT at 48±9% V̇O<sub>2</sub> prd). Overall, respiratory reserve was not exhausted in patients with COVID-19. Ventilatory equivalents for V̇O<sub>2</sub> (V<sub>E</sub>/V̇O<sub>2</sub>) and V̇CO<sub>2</sub> (V<sub>E</sub>/V̇CO<sub>2</sub>), and transcutaneous carbon dioxide tension (TcCO<sub>2</sub>) were compatible with exercise hyperventilation (Table 1). A recent study in survivors from COVID-19 pneumonia has suggested that exercise hyperventilation after COVID-19 is frequent and principally due to enhanced chemoreflex sensitivity rather than increased V<sub>D</sub>/V<sub>T</sub>.<sup>4</sup> We observed a mild reduction in arterial oxygen saturation (SpO<sub>2</sub>). Arterial blood pressure was normal, whereas the mean heart rate reached approximately 80% of predicted normal value. Sensations of breathlessness and leg discomfort were indicative of severe symptoms. The predominant symptom for stopping exercise was breathlessness (6/14), leg discomfort (2/14) or both dyspnoea and leg discomfort (6/14). Exercise endurance time was not different between IE compared to CLE (p = 0.1594, Table 2). The average cycling work rate did not differ between IE and CLE. The same was also the case for V̇O<sub>2</sub> and for both ventilatory equivalents (Table 2). At the limit of cycling tolerance, none of the ventilatory or cardiovascular responses differed between IE and CLE (Table 2) and there was no difference in the intensity of breathlessness or leg discomfort between the two modalities. The ventilatory reserve, reflected by the ratio of V<sub>E</sub>/maximal voluntary ventilation (V<sub>E</sub>/MVV), did not differ between IE and CLE. During CLE and IE 36% and

<https://doi.org/10.1016/j.pulmoe.2022.02.005>

2531-0437/© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1** Demographic, anthropometric and clinical characteristics.

Measures	
Patients, n	14
Age, years	63.1±12.9
BMI, kg/m <sup>2</sup>	28.0±5.2
Male, n (%)	11 (78.6%)
Comorbidities	
None, n (%)	9 (64.3%)
Cardiac, n (%)	3 (20.0%)
Respiratory, n (%)	2 (14.3%)
Diabetes, n (%)	1 (7.1%)
Hypertension, n (%)	9 (65.0%)
Days since acute hospitalisation, n	54.6± 22.0
Functional status	
SPPB, score	9.9±1.9
6MWD, m	411.4±111.6
6MWD, % of predicted	77.3±17.9
Physiological responses at the limit of tolerance during the CPET	
WRpeak, Watts	87.1±31.5
WRpeak, % predicted	59.4±22.1
VO <sub>2</sub> peak, ml/kg/min	12.7±4.6
VO <sub>2</sub> peak, % of predicted	57.6±16.2
VCO <sub>2</sub> peak, ml/kg/min	13.0±4.8
VO <sub>2</sub> -AT, ml/kg/min	10.6±3.2
VO <sub>2</sub> -AT, % VO <sub>2</sub> peak predicted	48.2±9.4
V <sub>E</sub> /VO <sub>2</sub> peak	50.4±10.4
V <sub>E</sub> /VCO <sub>2</sub> peak	40.6±9.2
RER peak	1.1±0.1
TcCO <sub>2</sub> peak, mmHg	37.4±5.3
V <sub>E</sub> peak, l/min	46.8±20.7
V <sub>E</sub> /MVV, %	42.5±17.1
SBPpeak, mmHg	171.8±26.4
DBPpeak, mmHg	96.6±14.2
SpO <sub>2</sub> peak, %	92.5±3.3
HRpeak, beats/min	124.3±2.3
HRpeak, % of predicted	79.0±10.4
Borg dyspnea at peak exercise, score	7.4±2.3
Borg Leg discomfort at peak exercise, score	5.8±3.1

**Legend:** Results are expressed as mean± Standard Deviation; BMI, body mass index; SPPB, Short Physical Performance Battery; 6MWD, six minute walking distance; CPET, cardiopulmonary exercise test; WRpeak, maximum load in watts at peak exercise; VO<sub>2</sub>, oxygen uptake; V<sub>E</sub>, ventilation; SpO<sub>2</sub>, peripheral oxygen saturation; TcCO<sub>2</sub>, transcutaneous carbon dioxide tension; VO<sub>2</sub>-AT, oxygen uptake at the anaerobic threshold; RER, respiratory exchange ratio; V<sub>E</sub>/VO<sub>2</sub>; ventilatory equivalent for VO<sub>2</sub>, V<sub>E</sub>/VCO<sub>2</sub>, ventilatory equivalent for VCO<sub>2</sub>; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR, heart rate.

21% of patients, respectively, ended the test with a HR greater than 80% of maximal predicted. Forty-three percent of patients ended CLE and 50% ended IE with a decrease in SpO<sub>2</sub> greater than 4%, compatible with exercise-induced arterial oxygen desaturation. The fraction of patients who

reasoned dyspnoea as the limiting factor was identical between IE and CLE corresponding to 57%. The fraction of patients who stopped exercise because of leg discomfort was relatively low for IE (n=2, 14%) and for CLE (n=3; 21%). Both dyspnoea and leg discomfort as the limiting factors were reported by n=4 for IE (29%) and n=3 for CLE (22%). At exercise iso-time and the limit of tolerance during IE and CLE protocols, V<sub>E</sub>, SPO<sub>2</sub> and VO<sub>2</sub> did not differ (Table 2). Moreover, symptoms for breathlessness, leg discomfort, heart rate or blood pressure measurements were not different during IE and CLE protocols.

The lack of adverse events occurring during exercise modalities was in line with previous studies on COVID-19 survivors.<sup>5</sup> Moreover, several studies on other ‘high risk’ patients’ groups (e.g., such as ischemic heart disease and heart failure) showed that high-intensity exercise is considered safe.<sup>6,7</sup> Recent studies in COVID-19 survivors<sup>4,8</sup> have attributed early metabolic acidosis to myopathic changes occurring for medications administered during the hospital stay (e.g., steroids) as well as because of the potential direct or indirect myopathic damage from COVID-19 rather than muscle disuse.<sup>7</sup> Hence, several opinion papers and guidelines favour low-intensity exercise with gradual increases in intensity, mostly due to safety concerns.<sup>2,3</sup> Early experiences of rehabilitation in post-COVID-19<sup>5</sup> individuals show that low-to-moderate intensity of exercise in this population is safe and effective in improving exercise tolerance and peripheral muscle strength. Accordingly, our study was designed to investigate the safety and tolerability of high-intensity (continuous or interval) exercise in this population.

Individuals with ongoing symptomatic COVID-19 could successfully and safely undertake high-intensity exercise performed continuously or intermittently. These findings are relevant both for a better understanding of consequences of COVID-19 on exercise tolerance. They also provide a clearer suggestion to survivors on how they should undertake regular exercise when expecting to resume their previous lifestyle.

## Acknowledgments

The authors thank Laura Comini and Adriana Olivares for technical assistance. This work was supported by the “Ricerca Corrente” Funding scheme of the Ministry of Health, Italy.

## Author contributions

MP (Guarantor) had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects. MV, IV, MP and MVe contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. BS, LB contributed to data collection and interpretation. All Authors reviewed the manuscript.

**Table 2** Responses at the limit of tolerance (Tlim) to constant-load exercise (CLE) and interval exercise (IE) protocols.

	Tlim_CLE	Tlim_IE	P
<b>Cycling responses</b>			
Work rate, Watts	59.6±23.4	60.0±23.2	0.4845
Endurance time, min	12.7±8.5	14.7±9.0	0.1594
Cadence, rpm	60.2±7.1	59.1±7.0	0.9150
Total work, kJ	45.9±31.2	54.3±40.2	0.1580
<b>Metabolic and ventilatory responses</b>			
VO <sub>2</sub> , ml/kg/min	12.3±3.8	11.9 ±3.2	0.6494
VO <sub>2</sub> , % VO <sub>2</sub> peak	94.6±18.9	95.6±24.3	0.8676
RER	0.9±0.1	0.9±0.1	0.4513
V <sub>E</sub> , L/min	46.9±22.3	44.3±16.8	0.5767
V <sub>E</sub> /MVV, %	41.4± 2.9	41.5±19.3	0.9927
VE/VO <sub>2</sub>	47.6±8.0	47.1±10.2	0.8157
V <sub>E</sub> /VCO <sub>2</sub>	52.0± 9.6	50.6± 10.6	0.2317
Ti, sec	0.7± 0.1	0.7±0.2	0.6128
Ti/Ttot	0.4±0.0	0.4±0.0	0.8041
Bf, breaths/min	35.9±6.4	36.1±7.1	0.8970
SpO <sub>2</sub> , %	92.9±3.6	92.3±3.4	0.1788
TcCO <sub>2</sub> , mmHg	33.4±4.0	32.5±4.5	0.2289
<b>Cardiovascular and symptoms responses</b>			
Mean BP, mmHg	119.9±18.7	113.1±8.2	0.1494
HR, beats/min	117.1±17.2	114.6 ±13.4	0.4712
HR, % of predicted	74.7±8.6	73.4±8.2	0.5681
Borg dyspnea, score	6.6±2.6	6.4±2.8	0.3456
Borg leg discomfort, score	5.0±3.0	4.3±3.3	0.2206

**Legend:** Results are expressed as mean± Standard Deviation; VO<sub>2</sub>, oxygen uptake; V<sub>E</sub>, minute ventilation; arterial oxygen saturation; TcCO<sub>2</sub>, transcutaneous carbon dioxide; CPET, cardiopulmonary exercise test; RER, respiratory exchange ratio; V<sub>E</sub>/VO<sub>2</sub>, ventilatory equivalent for VO<sub>2</sub>; V<sub>E</sub>/VCO<sub>2</sub>, ventilatory equivalent for VCO<sub>2</sub>; BP, blood pressure; HR, heart rate.

## Declaration of competing interest

The authors declare no conflict of interest related to this manuscript.

## References

- Sivan M, Taylor S. NICE guideline on long covid. *BMJ (Clin Res Ed)*. 2020;371:m4938. <https://doi.org/10.1136/bmj.m4938>.
- Vitacca M, Carone M, Clini EM, et al. Joint statement on the role of respiratory rehabilitation in the COVID-19 crisis: the Italian position paper. *Respiration*. 2020;99:493–9. <https://doi.org/10.1159/000508399>.
- Barker-Davies RM, O'Sullivan O, Senaratne KPP, et al. The Stanford hall consensus statement for post-COVID-19 rehabilitation. *Br J Sports Med*. 2020;54:949–59. <https://doi.org/10.1136/bjsports-2020-102596>.
- Baratto C, Caravita S, Faini A, et al. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. *J Appl Physiol (1985)*. 2021;130:1470–8. <https://doi.org/10.1152/jappphysiol.00710.2020>.
- Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh SJ. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition - a cohort study. *Chron Respir Dis*. 2021;18:14799731211015691. <https://doi.org/10.1177/14799731211015691>.
- Hermann M, Pekacka-Eglin AM, Witassek F, Baumgaertner R, Schoendorf S, Spielmanns M. Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19. *Am J Phys Med Rehabil*. 2020;99:865–9. <https://doi.org/10.1097/PHM.0000000000001549>.
- Batacan RB Jr, Duncan MJ, Dalbo VJ, Tucker PS, Fenning AS. Effects of high-intensity interval training on cardiometabolic health: a systematic review and meta-analysis of intervention studies. *Br J Sports Med*. 2017;51:494–503. <https://doi.org/10.1136/bjsports-2015-095841>.
- Skjørtén I, Ankerstjerne OAW, Trebinjac D, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. *Eur Respir J*. 2021;58:2100996. <https://doi.org/10.1183/13993003.00996-2021>.

M. Vitacca<sup>a,\*</sup>, I. Vogiatzis<sup>b</sup>, B. Salvi<sup>a</sup>,  
L. Bertacchini<sup>a</sup>, M. Venturelli<sup>c</sup>, M. Paneroni<sup>a</sup>

<sup>a</sup> *Respiratory Rehabilitation of the Institute of Lumezzane, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane (Brescia), Italy*

<sup>b</sup> *Department of Sport, Exercise and Rehabilitation; Faculty of Health and Life Sciences. Northumbria University, Newcastle, UK*

<sup>c</sup> *Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy*

\* Corresponding author at: Michele Vitacca MD FERS, Istituti Clinici Scientifici Maugeri IRCCS, Respiratory Rehabilitation of the Institute of Lumezzane (Brescia), Italy

E-mail address: [michele.vitacca@icsmaugeri.it](mailto:michele.vitacca@icsmaugeri.it) (M. Vitacca).

Received 23 November 2021; Accepted 15 February 2022

Available online 28 February 2022